🌍·12h agoResearch
Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.
Publisher
E
Europe PMC
EU
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Europe PMC
- Region
- EU
- Scope
- Research
- Published
- August 1, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on europepmc.org
Leave the platform to read the original full article on the publisher site.
Source: Europe PMC
Scope: Research
Related coverage
More related coverage
Europe PMC/12h ago
Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology.
Europe PMC/12h ago
A Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies.
Europe PMC/12h ago
Safety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First-in-Human, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Studies.
Europe PMC/12h ago